title: [A Case of Abdominal Wall Hernia Rupture during Bevacizumab Treatment].
abstract: A 78 -year-old man with rectal cancer underwent abdominoperineal resection of the rectum. In the postoperative period, the patient experienced wound infection, leading to an abdominal wall hernia. Two years following surgery, a rise in the serum CEA level was seen. A metastatic tumor was detected in the right lung on chest CT. VATS right lung inferior lobe segmental resection was performed. After lobectomy, the serum CEA level continued to increase. Another metastatic tumor was detected in the right lung on chest CT. Chemotherapy with capecitabine, oxaliplatin, and bevacizumab was commenced. The erosive part of the abdominal wall scar hernia extended during the nine weeks of chemotherapy. The chemotherapy was then discontinued. In the follow-up CT scan, a right pleural recurrence, local recurrence in the pelvis, and a liver metastasis were detected. Chemotherapy was re-introduced 3 years after surgery. The erosive part of the abdominal wall hernia again began to spread with chemotherapy recommencement. Four months after restarting chemotherapy, the hernia ruptured, with a loop of the small intestine protruding out of it. The patient covered this with a sheet of vinyl and was taken by the ambulance to our hospital. The erosive part of the abdominal wall hernia had split by 10 cm, and a loop of the small intestine was protruding. As ischemia of the small intestine was not observed, we replaced it into the abdominal cavity, and performed a temporary suture repair of the hernia sac. Following this, bevacizumab was discontinued, and the erosive part reduced. We performed a radical operation for abdominal wall scar hernia repair 11 weeks after the discontinuation of bevacizumab.
authors.affiliation: Dept. of Surgery, Kinan Hospital.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Sugimoto
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Sou
authors.initials: S
authors.lastname: Hirose
authors.forename: Toshiya
authors.initials: T
authors.lastname: Michiura
authors.forename: Shigeo
authors.initials: S
authors.lastname: Fujita
authors.forename: Kazuo
authors.initials: K
authors.lastname: Yamabe
authors.forename: Satoru
authors.initials: S
authors.lastname: Miyazaki
authors.forename: Makio
authors.initials: M
authors.lastname: Nagaoka
mesh_terms: D034861:Abdominal Wall / Q000473:pathology* / Q000601:surgery; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects*; D003131:Combined Modality Therapy; D046449:Hernia, Abdominal / Q000139:chemically induced / Q000601:surgery*; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary / Q000601:surgery; D008297:Male; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012008:Recurrence
chemical_list: D000068258:Bevacizumab